Estrella Immunopharma, Inc. 10-Q

Financial Statements (unaudited)

ITEM 1. FINANCIAL STATEMENTS. ESTRELLA IMMUNOPHARMA, INC. UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS As of June 30, 2026 As of December 31, 2025 (Unaudited) Current Assets Current assets: Cash and cash equivalents $ 146,670 $ 1,384,302 Prepaid expenses and other receivables 178,011 292,673 Prepaid expenses, related party 1,500,000 - Total current assets 1,824,681 1,676,975 Other Assets Prepaid expenses, related party, non-current - 1,500,000 Total Assets $ 1,824,681 $ 3,176,975 Liabilities and Stockholders’ (Deficit) Equity Current liabilities: Accounts payable - related party $ 8,232 $ 554,781 Other payables and accrued liabilities 255,559 238,414 Accrued liability - related party 8,304,999 12,393,333 Derivative liabilities 687,224 356,505 Total current liabilities 9,256,014 13,543,033 Total Liabilities 9,256,014 13,543,033 Commitments and Contingencies (Note 4) Preferred Stock Preferred Stock, $ 0.0001 par value, 10,000,000 shares authorized; 0 shares issued and outstanding as of June 30, 2026 and December 31, 2025 Stockholders’ Deficit: Common stock, $ 0.0001 par value; 250,000,000 shares authorized; 43,549,509 and 38,486,219 shares issued as of June 30, 2026 and December 31, 2025, respectively 4,355 3,849 Additional paid-in capital 34,751,909 27,219,287 Accumulated deficit ( 41,589,218 ) ( 36,990,815 ) Treasury stock, at cost 515,281 shares as of June 30, 2026 and December 31, 2025 ( 598,379 ) ( 598,379 ) Total Stockholders’ Deficit ( 7,431,333 ) ( 10,366,058 ) Total Liabilities and Stockholders’ Deficit $ 1,824,681 $ 3,176,975 The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. Field: Page; Sequence: 4; Options: NewSection; Value: 1 Field: Sequence; Type: Arabic; Name: PageNo 1 Field: /Sequence Field: /Page ESTRELLA IMMUNOPHARMA, INC. UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS For the Three Months Ended June 30, 2026 For the Three Months Ended June 30, 2025 For the Six Months Ended June 30, 2026 For the Six Months Ended June 30, 2025 Operating expenses Research and development (including $ 1,375,000 , $ 4,625,000 , $ 2,750,000 and $ 6,000,000 from a related party for the three months ended June 30, 2026 and 2025 and the six months ended June 30, 2026 and 2025, respectively) $ 1,400,232 $ 4,660,301 $ 2,800,507 $ 6,070,489 General and administrative (including $ 63,231 , $ 65,151